KR102865113B1 - 안정한 농축 방사성 핵종 복합체 용액 - Google Patents

안정한 농축 방사성 핵종 복합체 용액

Info

Publication number
KR102865113B1
KR102865113B1 KR1020247006883A KR20247006883A KR102865113B1 KR 102865113 B1 KR102865113 B1 KR 102865113B1 KR 1020247006883 A KR1020247006883 A KR 1020247006883A KR 20247006883 A KR20247006883 A KR 20247006883A KR 102865113 B1 KR102865113 B1 KR 102865113B1
Authority
KR
South Korea
Prior art keywords
dota
pharmaceutical
solution
neuroendocrine
aqueous solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020247006883A
Other languages
English (en)
Korean (ko)
Other versions
KR20240033296A (ko
Inventor
다니엘라 키코
도나토 바르바토
프란체스코 데 팔로
로렌차 푸가차
마우리치오 마리아니
조반니 테소리에레
클레멘티나 브람바티
Original Assignee
어드밴스드 엑셀러레이터 어플리케이션즈
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63794577&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102865113(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US16/045,484 external-priority patent/US20200030465A1/en
Priority claimed from PCT/IB2018/055575 external-priority patent/WO2020021310A1/en
Application filed by 어드밴스드 엑셀러레이터 어플리케이션즈 filed Critical 어드밴스드 엑셀러레이터 어플리케이션즈
Priority to KR1020257001675A priority Critical patent/KR102932818B1/ko
Publication of KR20240033296A publication Critical patent/KR20240033296A/ko
Application granted granted Critical
Publication of KR102865113B1 publication Critical patent/KR102865113B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/121—Solutions, i.e. homogeneous liquid formulation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • A61K51/048—DTPA (diethylenetriamine tetraacetic acid)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/083—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
KR1020247006883A 2018-07-25 2018-09-25 안정한 농축 방사성 핵종 복합체 용액 Active KR102865113B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020257001675A KR102932818B1 (ko) 2018-07-25 2018-09-25 안정한 농축 방사성 핵종 복합체 용액

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
IBPCT/IB2018/055575 2018-07-25
US16/045,484 2018-07-25
US16/045,484 US20200030465A1 (en) 2018-07-25 2018-07-25 Stable, concentrated radionuclide complex solutions
PCT/IB2018/055575 WO2020021310A1 (en) 2018-07-25 2018-07-25 Stable, concentrated radionuclide complex solutions
PCT/IB2018/057415 WO2020021322A1 (en) 2018-07-25 2018-09-25 Stable, concentrated radionuclide complex solutions
KR1020217005212A KR102643582B1 (ko) 2018-07-25 2018-09-25 안정한 농축 방사성 핵종 복합체 용액

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020217005212A Division KR102643582B1 (ko) 2018-07-25 2018-09-25 안정한 농축 방사성 핵종 복합체 용액

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020257001675A Division KR102932818B1 (ko) 2018-07-25 2018-09-25 안정한 농축 방사성 핵종 복합체 용액

Publications (2)

Publication Number Publication Date
KR20240033296A KR20240033296A (ko) 2024-03-12
KR102865113B1 true KR102865113B1 (ko) 2025-09-26

Family

ID=63794577

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020247006883A Active KR102865113B1 (ko) 2018-07-25 2018-09-25 안정한 농축 방사성 핵종 복합체 용액
KR1020267005571A Pending KR20260030955A (ko) 2018-07-25 2018-09-25 안정한 농축 방사성 핵종 복합체 용액
KR1020257001675A Active KR102932818B1 (ko) 2018-07-25 2018-09-25 안정한 농축 방사성 핵종 복합체 용액
KR1020217005212A Active KR102643582B1 (ko) 2018-07-25 2018-09-25 안정한 농축 방사성 핵종 복합체 용액

Family Applications After (3)

Application Number Title Priority Date Filing Date
KR1020267005571A Pending KR20260030955A (ko) 2018-07-25 2018-09-25 안정한 농축 방사성 핵종 복합체 용액
KR1020257001675A Active KR102932818B1 (ko) 2018-07-25 2018-09-25 안정한 농축 방사성 핵종 복합체 용액
KR1020217005212A Active KR102643582B1 (ko) 2018-07-25 2018-09-25 안정한 농축 방사성 핵종 복합체 용액

Country Status (23)

Country Link
EP (7) EP4640241A3 (https=)
JP (3) JP7402218B2 (https=)
KR (4) KR102865113B1 (https=)
CN (5) CN120860271A (https=)
AU (6) AU2018433575B2 (https=)
BR (1) BR112021001148A2 (https=)
CA (1) CA3153630A1 (https=)
CO (1) CO2021000506A2 (https=)
DE (3) DE202018006567U1 (https=)
DK (6) DK4545101T3 (https=)
ES (4) ES3064434T3 (https=)
FI (6) FI4541379T3 (https=)
HR (6) HRP20260338T1 (https=)
HU (1) HUE072720T2 (https=)
IL (4) IL319541B2 (https=)
LT (6) LT4541381T (https=)
MX (2) MX2021000805A (https=)
PL (5) PL3826686T3 (https=)
PT (6) PT4541381T (https=)
RS (5) RS67667B1 (https=)
SG (1) SG11202100645XA (https=)
SI (5) SI4545101T1 (https=)
WO (1) WO2020021322A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11541134B1 (en) 2021-08-02 2023-01-03 Rayzebio, Inc. Stabilized compositions of radionuclides and uses thereof
EP4442285A1 (en) * 2021-11-30 2024-10-09 Nihon Medi-Physics Co., Ltd. Stabilized radiopharmaceutical composition
US20260053959A1 (en) * 2022-02-04 2026-02-26 Advanced Accelerator Applications Methods for large scale synthesis of radionuclide complexes
CN114404618A (zh) * 2022-03-28 2022-04-29 北京先通国际医药科技股份有限公司 放射性药物水溶液及其用途
CN114404619A (zh) * 2022-03-28 2022-04-29 北京先通国际医药科技股份有限公司 放射性药物水溶液及其制备方法和用途
CN116920129A (zh) * 2022-04-02 2023-10-24 北京先通国际医药科技股份有限公司 放射性药物水溶液及其制备方法和用途
US20260102526A1 (en) * 2024-06-27 2026-04-16 Curium Us Llc 177lutetium-dota-tate formulations

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008009444A1 (en) 2006-07-19 2008-01-24 Van Dulmen, Adrianus, A. Use of ethanol for stabilizing a single-vial liquid formulation of a radiolabeled peptide

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2779780A (en) 1955-03-01 1957-01-29 Du Pont 1, 4-diamino-2, 3-dicyano-1, 4-bis (substituted mercapto) butadienes and their preparation
US4261989A (en) 1979-02-19 1981-04-14 Kaken Chemical Co. Ltd. Geldanamycin derivatives and antitumor drug
EP0647450A1 (en) 1993-09-09 1995-04-12 BEHRINGWERKE Aktiengesellschaft Improved prodrugs for enzyme mediated activation
US6066309A (en) * 1996-02-02 2000-05-23 Rhomed Incorporated Post-labeling stabilization of radiolabeled proteins and peptides
EP1143957A3 (en) 1998-12-16 2002-02-27 Warner-Lambert Company Treatment of arthritis with mek inhibitors
JP3811775B2 (ja) 2000-07-19 2006-08-23 ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー ４−ヨードフェニルアミノベンズヒドロキサム酸の酸素化エステル
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
PT1478648E (pt) 2002-02-01 2014-07-15 Ariad Pharma Inc Compostos contendo fósforo e suas utilizações
CN1653059A (zh) 2002-03-08 2005-08-10 卫材株式会社 用作医药品的大环化合物
KR100984595B1 (ko) 2002-03-13 2010-09-30 어레이 바이오파마 인크. Ｍｅｋ 억제제로서의 ｎ3 알킬화 벤즈이미다졸 유도체
TWI275390B (en) 2002-04-30 2007-03-11 Wyeth Corp Process for the preparation of 7-substituted-3- quinolinecarbonitriles
JP5139678B2 (ja) * 2003-07-24 2013-02-06 ブラッコ・イメージング・ソシエタ・ペル・アチオニ 安定な放射性医薬品組成物およびその製法
CA2618218C (en) 2005-07-21 2015-06-30 Ardea Biosciences, Inc. N-(arylamino)-sulfonamide inhibitors of mek
CA3042737A1 (en) * 2016-11-04 2018-05-11 Clarity Pharmaceuticals Pty Ltd Formulations for radiotherapy and diagnostic imaging
US10596276B2 (en) 2018-07-25 2020-03-24 Advanced Accelerator Applications (Italy) S.R.L. Stable, concentrated radionuclide complex solutions

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008009444A1 (en) 2006-07-19 2008-01-24 Van Dulmen, Adrianus, A. Use of ethanol for stabilizing a single-vial liquid formulation of a radiolabeled peptide

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Erik de Blois 외. Application of single-vial ready-for-use formulation of 111In- or 177Lu-labelled somatostatin analogs. Applied Radiation and Isotopes. Vol. 85, 2014, pp. 28-33*

Also Published As

Publication number Publication date
ES3063402T3 (en) 2026-04-16
AU2025202231A1 (en) 2025-04-17
FI3826686T3 (fi) 2025-08-20
HRP20260237T1 (hr) 2026-04-10
DK4545101T3 (da) 2026-03-02
KR20240033296A (ko) 2024-03-12
IL319542A (en) 2025-05-01
LT4541381T (lt) 2026-03-25
PL3826686T3 (pl) 2025-09-22
IL319541B1 (en) 2025-09-01
IL319541A (en) 2025-05-01
LT3826686T (lt) 2025-08-25
JP2022501313A (ja) 2022-01-06
PT4545100T (pt) 2026-02-16
HRP20260100T1 (hr) 2026-04-10
IL313560B1 (en) 2025-07-01
MX2021000805A (es) 2021-05-12
LT4541380T (lt) 2026-03-10
PL4541379T3 (pl) 2026-03-23
IL280314A (en) 2021-03-25
LT4545101T (lt) 2026-03-10
CN112584875A (zh) 2021-03-30
AU2018433575A1 (en) 2021-02-11
WO2020021322A1 (en) 2020-01-30
KR20260030955A (ko) 2026-03-06
EP4545100B1 (en) 2025-12-10
RS67754B1 (sr) 2026-03-31
AU2025220852A1 (en) 2025-09-11
AU2025204901B2 (en) 2025-09-18
RS67667B1 (sr) 2026-02-27
PT4545101T (pt) 2026-02-24
FI4541379T3 (fi) 2026-02-17
BR112021001148A2 (pt) 2021-04-20
CN120860271A (zh) 2025-10-31
CA3153630A1 (en) 2020-01-30
IL313560A (en) 2024-08-01
AU2022203683A1 (en) 2022-06-16
EP4541380B1 (en) 2025-12-10
EP4541381A3 (en) 2025-07-23
FI4541381T3 (fi) 2026-04-01
HRP20260222T1 (hr) 2026-03-27
KR20210035855A (ko) 2021-04-01
EP4545101A3 (en) 2025-07-23
AU2018433575B2 (en) 2022-07-07
DE202018007006U1 (de) 2025-11-13
FI4545100T3 (fi) 2026-03-02
EP4541379A3 (en) 2025-07-23
AU2024201217A1 (en) 2024-03-14
SG11202100645XA (en) 2021-02-25
FI4545101T3 (fi) 2026-02-24
CN120860270A (zh) 2025-10-31
RS67034B1 (sr) 2025-08-29
SI3826686T1 (sl) 2025-09-30
PL4545100T3 (pl) 2026-03-30
SI4541379T1 (sl) 2026-03-31
DK4541379T3 (da) 2026-02-02
DE202018006567U1 (de) 2021-04-01
MX2025012060A (es) 2025-11-03
IL319541B2 (en) 2026-01-01
ES3064589T3 (en) 2026-04-27
AU2022203683B2 (en) 2023-12-21
JP7402218B2 (ja) 2023-12-20
EP4545100A2 (en) 2025-04-30
HRP20250912T1 (hr) 2025-09-26
ES3038413T3 (en) 2025-10-13
LT4541379T (lt) 2026-02-10
EP3826686B1 (en) 2025-05-21
FI4541380T3 (fi) 2026-03-02
AU2024201217B2 (en) 2025-02-27
EP4640241A2 (en) 2025-10-29
JP7796696B2 (ja) 2026-01-09
EP4541380A3 (en) 2025-07-23
HUE072720T2 (hu) 2025-12-28
SI4545100T1 (sl) 2026-03-31
HRP20260338T1 (hr) 2026-04-10
EP4541381B1 (en) 2026-02-04
KR102932818B1 (ko) 2026-03-03
JP2025111424A (ja) 2025-07-30
IL313560B2 (en) 2025-11-01
PT4541380T (pt) 2026-02-24
PL4545101T3 (pl) 2026-03-30
EP4541381A2 (en) 2025-04-23
AU2025204901A1 (en) 2025-07-17
PL4541380T3 (pl) 2026-03-30
KR102643582B1 (ko) 2024-03-05
CO2021000506A2 (es) 2021-04-19
EP4545101B1 (en) 2025-12-10
EP4640241A3 (en) 2025-12-10
DK4545100T3 (da) 2026-02-23
EP4541380A2 (en) 2025-04-23
DK3826686T3 (da) 2025-08-25
RS67755B1 (sr) 2026-03-31
DK4541381T3 (da) 2026-04-07
PT4541381T (pt) 2026-03-17
KR20250017751A (ko) 2025-02-04
CN120860272A (zh) 2025-10-31
CN121081692A (zh) 2025-12-09
DE202018007007U1 (de) 2025-11-13
JP2023117417A (ja) 2023-08-23
IL319542B1 (en) 2026-04-01
HRP20260179T1 (hr) 2026-04-10
EP4541379B1 (en) 2025-11-19
AU2025220852B2 (en) 2025-10-23
RS67729B1 (sr) 2026-03-31
PT4541379T (pt) 2026-01-29
SI4545101T1 (sl) 2026-04-30
EP3826686A1 (en) 2021-06-02
EP4545100A3 (en) 2025-07-23
ES3064434T3 (en) 2026-04-24
LT4545100T (lt) 2026-02-25
PT3826686T (pt) 2025-08-04
DK4541380T3 (da) 2026-02-23
EP4545101A2 (en) 2025-04-30
EP4541379A2 (en) 2025-04-23
SI4541380T1 (sl) 2026-04-30

Similar Documents

Publication Publication Date Title
US12415003B2 (en) Stable, concentrated radionuclide complex solutions
US10596278B2 (en) Stable, concentrated radionuclide complex solutions
KR102865113B1 (ko) 안정한 농축 방사성 핵종 복합체 용액
US20210379213A1 (en) Stable, concentrated radionuclide complex solutions
HK40119655A (en) Stable, concentrated radionuclide complex solutions
HK40119656A (en) Stable, concentrated radionuclide complex solutions
HK40119658A (en) Stable, concentrated radionuclide complex solutions
HK40119657A (en) Stable, concentrated radionuclide complex solutions
HK40119654A (en) Stable, concentrated radionuclide complex solutions

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)